← Back to Search

Smart Text Messaging for HIV/AIDS

N/A
Waitlist Available
Led By Damani Piggott, MD, PhD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
HIV-1 positive adults of any gender
Age 50 years and older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 12 weeks
Awards & highlights

Study Summary

This study is evaluating whether a mobile health text messaging platform linked to a digital physical activity tracker can improve physical activity in people living with HIV and frailty.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Mean daily step count
Secondary outcome measures
Change in Frailty as assessed by the Fried-based physical frailty phenotype
Change in Interleukin-6 (IL-6) concentration
Change in Muscle strength as assessed by isokinetic resistance
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Digital Activity Tracker/Smart Text MessagingExperimental Treatment3 Interventions
Group receives baseline physical activity counseling. Group receives personalized, health coaching via "smart" text messages informed by digital activity tracker.
Group II: Physical Activity CounselingPlacebo Group1 Intervention
Group receives baseline physical activity counseling. Group does not receive personalized, health coaching via "smart" text messages.

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,245 Previous Clinical Trials
14,816,486 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,265 Previous Clinical Trials
5,484,032 Total Patients Enrolled
Damani Piggott, MD, PhDPrincipal InvestigatorJohns Hopkins University

Frequently Asked Questions

~3 spots leftby Mar 2025